Events

Speakers include Cameron Bess, Project Officer, Antibacterials Branch, Division of CBRN Medical Countermeasures, BARDA. Turning a good scientific idea into a successful biotech startup is a challenging journey.This panel will highlight several successful paths that scientists can take toward creating a successful biotech company. Learn what New York-area resources are available to turn your idea […]

AMR in the Light of COVID-19 - A Webinar Series Each of us is now living in a world with a nearly untreatable virus - but COVID-19 is not the only threat that we are facing. Many bacterial and fungal infections that were previously considered treatable are no longer responding to the drugs designed to […]

Participants include Kevin Outterson, Executive Director of CARB-X. The world needs a new generation of antibiotics to address the rapid growth in antibiotic-resistant bacteria. The UK government’s 2014 Review on Antimicrobial Resistance estimated that such bacteria could result in the deaths of 10 million people a year by 2050 and an accumulated cost of up […]

AMR in the Light of COVID-19 - A Webinar Series Each of us is now living in a world with a nearly untreatable virus - but COVID-19 is not the only threat that we are facing. Many bacterial and fungal infections that were previously considered treatable are no longer responding to the drugs designed to […]

Speakers: Value of a pre-IND interaction with the US FDA during late lead optimization: Bugworks experience - Bala Subramanian, Bugworks Research Inc. Amicidins: Building clinical and regulatory strategies for non-traditional products to prevent and treat life-threatening infections - Michael P. Bevilacqua, Amicrobe, Inc. Discovery and development of microbiome therapeutics using reverse translation - Matthew Henn […]

Recent CARB-X graduate, Specific Diagnostics, will be participating in this workshop. This workshop will be a forum for start-up and SMEs developing diagnostic tests to: Hear from successful entrepreneurs who have built diagnostic companies, what do they think were their key factors for success? Hear from venture capital investors about what they expect and need […]